CIZUTAMIG
UNII P5TLS56PWW

Substance Identification & Data

This profile provides standardized clinical and technical data for Cizutamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) P5TLS56PWW.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2919209-65-5 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

P5TLS56PWW

CAS Registry Number

2919209-65-5

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

CIZUTAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C179632

National Cancer Institute reference terminology for clinical and research data.

INN ID

13166

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-169

Identifier assigned by the United States Adopted Names Council.

Substance Type

Cizutamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Cizutamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Cizutamig

Common Names & Synonyms

CIZUTAMIG [USAN]

EMB 06 [WHO-DD]

Immunoglobulin G1, bispecific, anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal EMB-06 κ-chain) fusion protein with immunoglobulin G1 anti-(human CD3 antigen ε-chain) (human-Mus musculus monoclonal EMB-06 γ1-chain), disulfide with human monoclonal EMB-06 κ-chain, dimer, (Cys214→Cys224′′),(Cys214′→Cys224′′′)-bis(disulfide) with immunoglobulin G1 Fab fragment anti-(human tumor necrosis factor receptor superfamily protein TNFRSF17) (human-Mus musculus monoclonal EMB-06 γ1-chain)

cizutamig [INN]

fused L-kappa-H-gamma1 heavy chain anti-TNFRSF17 and anti-CD3E humanized (1-663) [[L-kappa anti-TNFRSF17 humanized (1-214) [V-KAPPA (Homo sapiens IGKV1-39*01 (82.1%) -IGKJ2*02 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153), V101 (191)) (108-214)] -H-gamma1 heavy chain anti-CD3E humanized (215-663) [VH (Homo sapiens IGHV1-2*02 (82.7%) -(IGHD) -IGHJ4*01 (93.3%) L123>T (328), CDR-IMGT [8.8.12] (240-247.265-272.311-322)) (215-333) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120, CH3 E12, M14, IGHG1v14 CH2 A1.3, A1.2 (CH1 R120>K (430) (334-431), hinge 1-15 (432-446), CH2 L1.3>A (450), L1.2>A (451) (447-556), CH3 E12 (572), M14 (574) (557-661), CHS (662-663)) (334-663)]]; (214-224')-disulfide with VH-G1(CH1-h) light chain anti-TNFRSF17 humanized (1'-224') [VH (Homo sapiens IGHV1-3*03 (84.7%) -IGHD -IGHJ4*01 (92.3%) L123>T (116'), CDR-IMGT [8.8.14] (26'-33'.51'-58'.97'-110')) (1'-121') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, CH1 K120 (CH1 R120>K (218') (122'-219'), hinge 1-5 (220'-224')) (122'-224')]]; (436-219''')-disulfide with L-kappa light chain anti-CD3E humanized (1'''-219''') [V-KAPPA (Homo sapiens IGKV4-1*01 (91.8%) -IGKJ4*01 (100%), CDR-IMGT [12.3.8] (27'''-38'''.56'''-58'''.95'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'''), V101 (196''')) (113'''-219''')]; dimer (442-442'':445-445'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, glycoform alfa

immunoglobulin [L-kappa-H-gamma1_[VH-G1(CH1-h)]_Lkappa] dimer, anti-[Homo sapiens TNFRSF17 (tumor necrosis factor (TNF) receptor superfamily member 17, B cell maturation antigen, BCMA, TNFRSF13A, CD269)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bispecific;